Vipoglanstat: A New Star of Next Generation Anti inflammatory Therapy – A Comprehensive Analysis from Mechanism of Action to Clinical Progress
Product Manager Email:ada@coreychem.com
Vipoglanstat (also known as BI 1029539, GS-248) is a novel, orally administered, highly selective small molecule microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor that is being developed for the treatment of inflammatory diseases such as endometriosis and systemic sclerosis associated Raynaud’s phenomenon. This article provides a systematic review of the chemical structure, mechanism of action, preclinical research results, clinical trial progress, and safety data of Vipoglanstat, aiming to provide comprehensive scientific references for pharmaceutical researchers and clinical doctors.
1、 New targets for inflammation treatment
Non steroidal anti-inflammatory drugs are the most commonly used anti-inflammatory and analgesic drugs in clinical practice, which block the synthesis of prostaglandins by inhibiting cyclooxygenase. However, long-term use of NSAIDs increases the risk of cardiovascular adverse events such as myocardial infarction, stroke, hypertension, and heart failure. These adverse reactions stem from the “broad-spectrum” blockade of prostaglandin synthesis by COX inhibitors – they not only inhibit pro-inflammatory prostaglandin E2, but also inhibit prostacyclin (PGI2), which has anti thrombotic and vasodilatory effects.
It is in this context that mPGES-1 has become a highly attractive alternative target. MPGES-1 is a terminal enzyme in the PGE2 biosynthesis pathway, which is induced to express under inflammatory stimulation and functionally coupled with COX-2. Selective inhibition of mPGES-1 can block pro-inflammatory PGE2 while preserving or even enhancing PGI2 production, theoretically providing better cardiovascular safety.
Vipoglanstat is a novel mPGES-1 inhibitor developed based on this concept, which has entered phase II clinical development for multiple indications.
2、 Chemical information
Name: Vipoglanstat
MF： C30H34Cl2F5N5O3
MW： 678.52
CAS： 1360622-01-0
Structural formula：
XLogP: 7.86 (indicating high lipophilicity)
Number of hydrogen bond acceptors: 6
Number of hydrogen bond donors: 3
Number of rotatable keys: 13
Topological polarity surface area: 97.28 Å ²
Solubility: The solubility in DMSO is 150 mg/mL (221.07 mM), and ultrasound assisted dissolution is required
Storage conditions: Powder stored at 4 ° C, away from light and moisture; Solution can be stable for 6 months at -80 ° C
The molecular structure of Vipoglanstat includes a benzimidazole core skeleton and multiple halogen substituents (chlorine, fluorine, trifluoromethyl), which endow it with high selectivity and oral bioavailability. Its chemical structure was first disclosed in Boehringer Ingelheim’s patent WO2012022793A1
3、 Mechanism of action
3.1 Target: mPGES-1
Microsomal prostaglandin E synthase-1 is a key enzyme in the arachidonic acid metabolism pathway. Under inflammatory stimulation, mPGES-1 is induced to express in various cells, including macrophages, fibroblasts, and endothelial cells, converting COX-2 derived PGH2 into PGE2.
PGE2 is one of the most important pro-inflammatory mediators, involved in pathological and physiological processes such as fever, pain perception, vasodilation, and inflammatory exudation. In endometriosis, PGE2 is highly expressed in ectopic lesions, driving inflammatory responses and pain.
3.2 Inhibition effect of Vipoglanstat
Vipoglanstat is an efficient and selective mPGES-1 inhibitor:
In vitro efficacy: IC50 of 0.4 nM in human whole blood test, showing super strong inhibitory activity
Target selectivity: No affinity for mouse derived mPGES-1, which is an important reason why its preclinical research requires the use of humanized transgenic mouse models
Pathway effect: Inhibiting mPGES-1 can bring dual beneficial effects – reducing PGE2 levels and increasing prostacyclin levels
This dual effect is the key advantage that distinguishes Vipoglanstat from traditional NSAIDs. Research data shows that Vipoglanstat can reduce PGE2 metabolites in urine by 57%, while increasing prostacyclin metabolites by 50%. The characteristic of “anti-inflammatory without damaging blood vessels” avoids the inhibition of cardiovascular protective prostacyclin.
4、 Preclinical research results
4.1 Myocardial infarction and vascular injury model
A study published in Scientific Reports in 2025 evaluated the efficacy of Vipoglanstat in myocardial infarction and vascular injury models using humanized mPGES-1 transgenic mice.
Main findings:
Improving cardiac function: Both pre-treatment and post-treatment with Vipoglanstat significantly improved left ventricular function and reduced myocardial hypertrophy
Advantages in reducing mortality rate: The treatment group had a 100% four week survival rate, while the COX-2 inhibitor celecoxib group experienced persistent mortality
Inhibition of neointimal formation in blood vessels: Vipoglanstat inhibits the migration and proliferation of carotid smooth muscle cells, reducing neointimal formation after vascular injury
Restoring blood pressure: effectively restoring the reduced mean arterial pressure after myocardial infarction
Research conclusion: Vipoglanstat exhibits good safety characteristics in the cardiovascular system and has therapeutic potential in reducing adverse remodeling after myocardial infarction and vascular injury.
4.2 Endometriosis Model
In preclinical models of endometriosis, Vipoglanstat showed:
Pain relieving behavior
Reduce lesion burden
These effects are consistent with the results observed in mPGES-1 knockout mice
5、 Safety and tolerability
Based on existing clinical data, Vipoglanstat demonstrates good safety features:
Overall safety: Safe and well tolerated at doses that achieve complete mPGES-1 inhibition in healthy volunteers and patients with chronic inflammatory diseases
Adverse events: The spectrum of adverse events is similar to that of the placebo group
Cardiovascular safety advantages: Unlike COX-2 inhibitors, Vipoglanstat does not increase mortality in myocardial infarction models, but instead improves heart function
Retaining prostacyclin: This is the core safety advantage that distinguishes it from traditional NSAIDs and colchicines
6、 New hope for non hormonal treatment of endometriosis
6.1 Unsatisfied clinical needs
Endometriosis affects approximately 190 million women worldwide, and it takes an average of 7-10 years from initial symptoms to diagnosis. The current standard treatment still mainly relies on hormone suppression, but it is accompanied by the following issues:
Side effects similar to menopause
The impact on fertility
High recurrence rate of symptoms
Some patients have poor response to hormone therapy
6.2 Differentiation advantages of Vipoglanstat
Vipoglanstat, as a non hormonal, non opioid oral medication, has the following potential advantages:
Not interfering with hormone axis: does not affect fertility
No steroid side effects: does not induce menopausal symptoms
Targeted anti-inflammatory: directly acting on the inflammatory pathway of the lesion
Novel mechanism of action: the first mPGES-1 inhibitor to enter phase II clinical trials of endometriosis
The label ‘non hormonal, non opioid’ makes Vipoglanstat unique in the field of endometriosis treatment.
7、 Competitive landscape and market prospects
7.1 Trends in Drug Development for Endometriosis
In recent years, research and development activities for endometriosis have significantly increased, but only a few drugs have been successfully marketed, and most still rely on hormone control mechanisms. This leaves ample market space for targeted anti-inflammatory and disease modifying drugs, such as Vipoglanstat.
7.2 Localization of Vipoglanstat
If a positive result is obtained from the NOVA test, it will verify the feasibility of mPGES-1 as a novel therapeutic target for endometriosis and may make Vipoglanstat the first non hormonal, targeted anti-inflammatory oral drug in this field.
8、 Summary and Prospect
Vipoglanstat represents the direction of next-generation anti-inflammatory drug development – achieving precise inflammatory pathway intervention by targeting end effector enzymes to avoid cardiovascular risks caused by broad-spectrum COX inhibition.
Product Manager Email:ada@coreychem.com
